Exact Mass: 495.3824574
Exact Mass Matches: 495.3824574
Found 207 metabolites which its exact mass value is equals to given mass value 495.3824574,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Orlistat
Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AB - Peripherally acting antiobesity products C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1].?Anti-atherosclerotic?effect[2].
LysoPC(16:0/0:0)
C24H50NO7P (495.33247200000005)
LysoPC(16:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:0), in particular, consists of one chain of palmitic acid at the C-1 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(16:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:0), in particular, consists of one chain of palmitic acid at the C-1 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPC(0:0/16:0)
C24H50NO7P (495.33247200000005)
LysoPC(0:0/16:0) is a lysophosphatidylcholine, which is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2 as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPC(0:0/16:0), in particular, consists of one chain of palmitic acid at the C-2 position.
(13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine
(13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine is an acylcarnitine. More specifically, it is an (13Z,16Z)-3-hydroxydocosa-13,16-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(14Z)-Tricos-14-enoylcarnitine
C30H57NO4 (495.42873620000006)
(14Z)-Tricos-14-enoylcarnitine is an acylcarnitine. More specifically, it is an (14Z)-tricos-14-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (14Z)-Tricos-14-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (14Z)-Tricos-14-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(18Z)-Tricos-18-enoylcarnitine
C30H57NO4 (495.42873620000006)
(18Z)-Tricos-18-enoylcarnitine is an acylcarnitine. More specifically, it is an (18Z)-tricos-18-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (18Z)-Tricos-18-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (18Z)-Tricos-18-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(17Z)-Tricos-17-enoylcarnitine
C30H57NO4 (495.42873620000006)
(17Z)-Tricos-17-enoylcarnitine is an acylcarnitine. More specifically, it is an (17Z)-tricos-17-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (17Z)-Tricos-17-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (17Z)-Tricos-17-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9Z)-Tricos-9-enoylcarnitine
C30H57NO4 (495.42873620000006)
(9Z)-Tricos-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-tricos-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-Tricos-9-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (9Z)-Tricos-9-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Nervonoyl Glutamic acid
N-nervonoyl glutamic acid, also known as N-nervonoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Glutamic acid is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
1-Nonadecanoyl-glycero-3-phosphoethanolamine
C24H50NO7P (495.33247200000005)
N(4)-Octadecyl-1-arabinofuranosylcytosine
C27H49N3O5 (495.36720240000005)
1-Palmitoylphosphatidylcholine
C24H50NO7P (495.33247200000005)
1-O-hexadecyl-2-C-methyl-3-phosphatidylcholine
C25H54NO6P (495.36885540000003)
Acquisition and generation of the data is financially supported by the Max-Planck-Society
cyclo (-Gly-L-Orn-L-Ile-3-amino-10-methyldodecanoyl-)|rhodopeptin C2
C26H49N5O4 (495.37843540000006)
lycoperine A
An alkaloid that consists of piperidine substituted by [1-acetyl-7-methyl-1,2,3,4,6,7,8,8a-octahydroquinolin-5-yl]methyl moieties at positions 2 and 6 respectively. Isolated from Lycopodium hamiltonii, it exhibits acetylcholinesterase inhibitory activity.
dysoxyhainanin A
C31H45NO4 (495.33484100000004)
A pentacyclic triterpenoid with a rearranged oleanane skeleton isolated from the whole plants of Dysoxylum hainanense. It exhibits antibacterial activity against Gram-positive bacteria.
cyclo (-GlyL-Orn-L-Val-3-amino-12-methyltridecanoyl-)|rhodopeptin C3
C26H49N5O4 (495.37843540000006)
1-O-Hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
Orlistat
A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AB - Peripherally acting antiobesity products C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors CONFIDENCE standard compound; INTERNAL_ID 2362 CONFIDENCE standard compound; INTERNAL_ID 8541 Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1].?Anti-atherosclerotic?effect[2].
PC(16:0/0:0)
C24H50NO7P (495.33247200000005)
CONFIDENCE standard compound; INTERNAL_ID 121 COVID info from WikiPathways Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Lysophosphatidylcholines, egg
C24H50NO7P (495.33247200000005)
LPC 16:0
C24H50NO7P (495.33247200000005)
Annotation level-2
1-Palmitoyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
LysoPhosphatidylcholine_16_0
C24H50NO7P (495.33247200000005)
1-Palmitoyllysophosphatidylcholine
C24H50NO7P (495.33247200000005)
Platelet-activating factor
C24H50NO7P (495.33247200000005)
PC(O-1:0/O-16:0)[U]
C25H54NO6P (495.36885540000003)
PC(O-16:0/O-1:0)
C25H54NO6P (495.36885540000003)
PC(O-16:0/O-1:0)[S]
C25H54NO6P (495.36885540000003)
ET 16OME
C25H54NO6P (495.36885540000003)
16:0 LYSO-PC
C24H50NO7P (495.33247200000005)
PC(16:0/0:0)[S]
C24H50NO7P (495.33247200000005)
PC(16:0/0:0)[U]
C24H50NO7P (495.33247200000005)
PC(0:0/16:0)
C24H50NO7P (495.33247200000005)
Palmi
C24H50NO7P (495.33247200000005)
PC(O-17:0/0:0)
C25H54NO6P (495.36885540000003)
2-O-methyl PAF C-16
C25H54NO6P (495.36885540000003)
LPE O-19:1;O
C24H50NO7P (495.33247200000005)
Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride
buta-1,3-diene,2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate,prop-2-enenitrile,styrene
C31H45NO4 (495.33484100000004)
N-Formyl-L-leucine (3S,4R,6S)-3-Hexyl-3,4,5,6-tetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester
(3-Hexadecoxy-2-hydroxy-2-methylpropyl) 2-(trimethylazaniumyl)ethyl phosphate
C25H54NO6P (495.36885540000003)
N-(2-hydroxydodecanoyl)-sphinga-4,8-dienine
C30H57NO4 (495.42873620000006)
N-hexanoylphytosphingosine 1-phosphate
C24H50NO7P (495.33247200000005)
(16Z,19Z,22Z,25Z,28Z,31Z)-tetratriacontahexaenoate
C34H55O2- (495.42018299999995)
A polyunsaturated fatty acid anion that is the conjugate base of (16Z,19Z,22Z,25Z,28Z,31Z)-tetratriacontahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(2-Octanoyloxy-3-octoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[(2S)-2-hexadecanoyloxy-3-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] propanoate
C24H50NO7P (495.33247200000005)
1-o-Heptadecyl-2-hydroxy-sn-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
2-Aminoethyl (2-hydroxy-3-icosoxypropyl) hydrogen phosphate
C25H54NO6P (495.36885540000003)
(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octadeca-3,6,9,12,15-pentaenamide
(2-Heptanoyloxy-3-nonoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] octanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] decanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] hexanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] nonanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] heptanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] undecanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] acetate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] butanoate
C24H50NO7P (495.33247200000005)
(3-Decoxy-2-hexanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Butanoyloxy-3-dodecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Propanoyloxy-3-tridecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Pentanoyloxy-3-undecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Acetyloxy-3-tetradecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]pentadecanamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxyoctadec-8-en-2-yl]dodec-5-enamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxyheptadeca-8,12-dien-2-yl]tridecanamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]hexadec-7-enamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]pentadec-9-enamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxyheptadec-8-en-2-yl]tridec-8-enamide
C30H57NO4 (495.42873620000006)
(4Z,7Z)-N-(1,3,4-trihydroxytetradecan-2-yl)hexadeca-4,7-dienamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]tetradecanamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxyoctadeca-8,12-dien-2-yl]dodecanamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]hexadecanamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxyhexadec-8-en-2-yl]tetradec-9-enamide
C30H57NO4 (495.42873620000006)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] pentanoate
C24H50NO7P (495.33247200000005)
2-[Hydroxy-[3-hydroxy-2-(nonanoylamino)decoxy]phosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[(2-Acetamido-3-hydroxyheptadecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(octanoylamino)undecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Hexanoylamino)-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Butanoylamino)-3-hydroxypentadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Heptanoylamino)-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(undecanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Decanoylamino)-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-Palmitoyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
A lysophosphatidylcholine 16:0 in which the acyl group is specified as palmitoyl (hexadecanoyl) and is located at position 2.
1-tetradecyl-2-acetyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as tetradecyl.
1-heptadecyl-sn-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
1-eicosyl-glycero-3-phosphoethanolamine
C25H54NO6P (495.36885540000003)
1-nonadecanoyl-glycero-3-phosphoethanolamine
C24H50NO7P (495.33247200000005)
1-(2-methoxy-6Z-octadecenyl)-sn-glycero-3-phosphoethanolamine
C24H50NO7P (495.33247200000005)
lysophosphatidylcholine 16:0
C24H50NO7P (495.33247200000005)
A lysophosphatidylcholine in which the acyl group has a fully saturated C16 chain and is attached to the glycero moiety at either position 1 or 2.
tetratriacontahexaenoate
A polyunsaturated fatty acid anion that is the conjugate base of tetratriacontahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Lysophosphatidylcholine(0:0/16:0)
C24H50NO7P (495.33247200000005)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 16 carbons and is fully saturated.
1-hexadecanoyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
A lysophosphatidylcholine 16:0 in which a hexadecanoyl (palmitoyl) group is attached to the glycero moiety at position 1.
LdMePE(17:0)
C24H50NO7P (495.33247200000005)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(18:0)
C25H54NO6P (495.36885540000003)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(19:0)
C24H50NO7P (495.33247200000005)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
AcCa(23:1)
C30H57NO4 (495.42873620000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(2-{[(2r)-3-(hexadecanoyloxy)-2-hydroxypropyl phosphonato]oxy}ethyl)trimethylazanium
C24H50NO7P (495.33247200000005)
(3s,6s,13r)-6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s)-6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s)-6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s,13r)-6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(2-{[(2r)-2-hydroxy-3-[(15-methylhexadecyl)oxy]propyl phosphonato]oxy}ethyl)trimethylazanium
C25H54NO6P (495.36885540000003)
(3s,6s,9r)-13-heptyl-5,8,11-trihydroxy-3-isopropyl-6,9-bis(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H49N3O5 (495.36720240000005)